The European Melanoma Registry
EUMelaReg collects real-world data from melanoma patients throughout Europe and securely integrates these datasets in a common database.
Geographical coverage
Datasets available
Participating countries
Join us!
Collecting real-world data from melanoma patients across Europe, we aim to build the largest and quickest melanoma registry in the world. Interested societies or cancer treatment centres can help us by joining EUMelaReg – even without an existing registry.
“While the total number of cancer incidences is dropping, the number of cases of melanoma is increasing at a rate of 3-7% in many European countries. We need to analyse more data in order to improve diagnosis and develop novel therapies.”
Lidija Kandolf, Serbia
“A rapidly accumulating and massive high-quality real-life data can be obtained only when hands are joined. The conclusions we get from analysing such data allow us to better understand skin cancers and treatment effects. It allows us to formulate burning and important clinical questions and receive the results promptly, in real-time. This is a huge advantage that takes us one step further toward curing cancer. I'm proud to take part in this international collaborative project!”
Nethanel Asher, Israel
“Our advances and success in melanoma research are the result of a true team effort including international collaborations. World class cancer registries are highly needed for patient stratification strategies, as well as in order to translate the results of clinical trials in unselected patient populations and monitor patient care.”
Johanna Mangana, Switzerland
“Real-world data is crucial to validate clinical trial data. Generally, patients enrolled in clinical trials are selected in comparison to patients treated in real life (who are often in worse condition). Analysing data from a large number of real-life patients allows us to assess the true impact of new therapies in clinical practice. This is why a clinical registry such as the European Melanoma Registry is essential.”
Paolo Ascierto, Italy
“In recent years, we have witnessed revolutionary breakthroughs in treatment as well as rejuvenation of patients with melanoma, which poses new challenges for us. EUMelaReg has evolved into a valuable and even more powerful platform for in-depth analysis of clinical practice so far, enabling us to achieve better understanding and successful management of the condition. We are delighted to contribute to global knowledge with data from our real-world practice in Bulgaria.”
Iva Gavrilova, Bulgaria
“The agreement between Germany, Holland and Denmark in December 2017 to establish a European real-world clinical database on metastatic melanoma has proven its value. National databases in several European countries have since been established, and the growing number of patients in the EUMelareg database already have led to significant scientific contributions in the field of real-world evidence. These contributions is of utmost importance to confirm data from pivotal clinical trials on new drugs in melanoma treatment.”
Lars Bastholt, Denmark
“Being part of European Melanoma Registry enables us to gain deeper knowledge that not only refines our diagnosis and treatment strategies but by prioritizing accurate data, we also aim to significantly improve the quality of life and increase the survival rates of melanoma patients.”
Ermira Vasili, Albania
“EUMelaReg is aimed to become the largest melanoma registry in the world. As such, it provides reliable information about relevant questions that clinical trials do not answer.”
Enrique Espinosa, Spain
Benefits
Implementation of national registries
Provision of infrastructure
Data analysis through reknowned experts
Improved diagnosis and treatment